A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations. - Kwag E; Kim SD; Shin SH; Oak C; Park SJ; Choi JY; Hoon Yoon S; Kang IC; Jeong MK; Woo Lee H; Bang SH; Son JW; et al. (Integrative cancer therapies, 2024)